Liposomes Targeted by Anti-EGFR scFv Human Antibody for Treatment of Cancer
Updated time: 2024-10-09 17:03:26
Liposomes Targeted by Anti-EGFR scFv Human Antibody for Treatment of Cancer
Docket Number
10A-1080308
Announcement Date
2020-03-12
IP Status
JP 7302028、TW I856109
Abstract
This invention relates to a human single chain antibody (scFv) against epidermal growth factor receptor (EGFR). The single-chain antibody can be used as a guide for a chemotherapeutic drug for the treatment of high epithelial growth factor receptor-expressing tumors, improving treatment efficiency and reducing toxicity to normal tissues.
Technological Advantages
- The anti-EGFR scFv is selected from the naïve human scFv library. This human antibody will evade human anti-mouse antibody immune response, and should be less immunogenicity.
- The anti-EGFR scFv can direct chemotherapeutic drugs to high EGFR-expressing tumor tissue in vivo, so that this strategy enables to improve therapeutic efficacy and reduce toxicity to normal tissue compared to conventional chemotherapy.
- Targeting to EGFR can apply for multiple types of cancer.
- The scFv can be engineered to intact human IgG, which may be as a therapeutic antibody for cancer treatment.
- The anti-EGFR scFv can cross-react to mouse EGFR and is useful for evaluation of side effects
Applications of Technology
- As a homing beacon for drug delivery system with cytotoxic payloads.
- Application of molecular imaging diagnosis.
- As the target scFv for CAR-T cell therapy.
Inventor
Han-Chung Wu etc.
Contact person
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Liposomes Targeted by Anti-EGFR scFv Human Antibody for Treatment of Cancer